StreetInsider.com News Articles

Equillium Announces Poster Presentations at the 7th International AHR Conference

Tue, 29 Sep 2026 16:05:00 -0400

LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portugal.

“These studies further characterize the multi-modal activity of EQ504, including its effects on epithelial barrier repair and key immune pathways involved in inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer

Equillium Announces Poster Presentations at the 7th International AHR Conference

Tue, 29 Sep 2026 16:05:00 -0400

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers

Wed, 23 Sep 2026 08:00:00 -0400

TORONTO, ON / ACCESS Newswire / September 23, 2026 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company") today announced that Integrated Rewards, its Canadian card-linked rewards network, has launched "Celebrate Canadian," a new campaign designed to increase the visibility of Canadian brands across its merchant network and provide members with enhanced cash back incentives when shopping Canadian. The initiative responds to growing consumer interest in supporting Canadian brands while creating a timely commercial opportunity for Integrated Rewards to expand its merchant network, deepen member engagement and become an increasingly meaningful driver

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers

Wed, 23 Sep 2026 08:00:00 -0400

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Wed, 16 Sep 2026 08:30:00 -0400

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

A live webcast of the fireside chat may also be accessed on the Events & Presentations page, located under

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Wed, 16 Sep 2026 08:30:00 -0400

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

A live webcast of the fireside chat may also be accessed on the Events & Presentations page, located under

EQ Works and Pattison Media form one-year data partnership

Tue, 15 Sep 2026 08:01:17 -0400

EQ Inc. (TSXV: EQ), known as EQ Works, and Pattison Media Ltd. have announced a one-year partnership in which Pattison Media will embed EQ's ClearLake data and analytics platform into its media and advertiser offerings, beginning with its radio and digital network across Western Canada.

Under the agreement, Pattison Media will provide a multi-million-dollar package of promotional radio advertising inventory across its network of radio stations and digital news portals in exchange for access to EQ's ClearLake platform, proprietary data, and technology.

The arrangement is structured differently from a typical agency relationship. Rather than using ClearLake to support client campaign planning, Pattison

EQ Works and Pattison Media Announce Strategic Partnership to Power Next-Generation Radio Audience Intelligence

Tue, 15 Sep 2026 08:00:00 -0400

Partnership marks the first time a major Canadian broadcaster has embedded EQ's proprietary data and analytics platform directly into its media assets and advertiser offering

TORONTO, ON AND KAMLOOPS, BC / ACCESS Newswire / September 15, 2026 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions, and Pattison Media Ltd. ("Pattison Media or "Pattison"), one of Canada's largest privately owned radio broadcasters, today announced a one-year strategic partnership that will see Pattison Media embed EQ's proprietary ClearLake data and analytics platform directly into

EQ Works and Pattison Media Announce Strategic Partnership to Power Next-Generation Radio Audience Intelligence

Tue, 15 Sep 2026 08:00:00 -0400

Partnership marks the first time a major Canadian broadcaster has embedded EQ's proprietary data and analytics platform directly into its media assets and advertiser offering

Form 10-Q Equillium, Inc. For: Jun 30

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921364.html

Form 10-Q Equillium, Inc. For: Jun 30

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921364.html

Form SCHEDULE 13G Equillium, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921181.html

Form SCHEDULE 13G Equillium, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921181.html

Form 8-K Equillium, Inc. For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921088.html

Form 8-K Equillium, Inc. For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921088.html

Equillium, Inc. (EQ) Tops Q2 EPS by 1c

Thu, 13 Aug 2026 16:06:17 -0400

Equillium, Inc. (NASDAQ: EQ) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on Equillium, Inc. (EQ) click here.

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

Cash and cash equivalents of $57.2 million expected to fund operations into 2029

Form SCHEDULE 13G/A Equillium, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26911282.html

Form SCHEDULE 13G/A Equillium, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26911282.html

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

The analyst comments "We initiate coverage of EQ with a Buy rating and a $9 PT. We believe lead asset EQ504, an oral AhR agonist, offers an attractive risk-reward profile in IBD, with a UC P1 trial set to initiate in 3Q26 and data expected in 1H27. EQ504 combines biologically validated mechanism, colon-targeted delivery to enhance safety, and once-daily oral convenience. EQ504 has the potential to break the current efficacy ceiling, supported by its pleiotropic biology, which overlaps with obefazimod’s

Clear Street Starts Equillium (EQ) at Buy

Tue, 21 Jul 2026 16:17:57 -0400

Clear Street analyst Kaveri Pohlman initiates coverage on Equillium (NASDAQ: EQ) with a Buy rating and a price target of $9.00.

Piper Sandler Starts Equillium (EQ) at Overweight

Mon, 13 Jul 2026 04:02:18 -0400

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ: EQ) with a Overweight rating and a price target of $20.00.

The analyst comments: “We are initiating coverage on Equillium, Inc. (EQ) with an OW rating and $20 PT, where we believe EQ is significantly undervalued compared to competitors within the UC space. Notably, their lead asset is EQ504, an AhR modulator clinically validated by indigo naturalis and obefazimod yet instilled with potential for higher potency and differentiated colontargeted engagement for cleaner safety. Accordingly, we review this depth of data from 4 studies of AhR modulators and obefazimod which collectively rationalize